Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinoma

about

Urothelial carcinoma of donor origin in a kidney transplant patient.

P2860

Q37346088-2A2EE220-8BBA-4B89-A990-F93487877890

P2860

Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinoma

Item

http://www.wikidata.org/entity/Q39564761

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Revision of immunosuppression ...... tic undifferentiated carcinoma

@en

Revision of immunosuppression ...... ic undifferentiated carcinoma.

@nl

type

Item

label

Revision of immunosuppression ...... tic undifferentiated carcinoma

@en

Revision of immunosuppression ...... ic undifferentiated carcinoma.

@nl

prefLabel

Revision of immunosuppression ...... tic undifferentiated carcinoma

@en

Revision of immunosuppression ...... ic undifferentiated carcinoma.

@nl

P1476

Revision of immunosuppression ...... tic undifferentiated carcinoma

@en

P2093

Abigail H Waldman

http://www.w3.org/2001/XMLSchema#string

AnnMarie Liapakis

http://www.w3.org/2001/XMLSchema#string

Jennifer M McNiff

http://www.w3.org/2001/XMLSchema#string

William S Asch

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the role of mTOR in cancer

The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.

Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience.

Translating gene expression into clinical care: sarcomas as a paradigm.

Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients.

Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial.

Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.

Sirolimus and secondary skin-cancer prevention in kidney transplantation.

P304

S8-S11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1016/J.JDCR.2015.09.010

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

S Smith-Marrone

Oscar R Colegio

P577

2015-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284786331

http://www.w3.org/2001/XMLSchema#string

P698

27051810

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

P932

4809581

http://www.w3.org/2001/XMLSchema#string

Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinoma

about

P2860

P2860

Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinoma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932